This site is intended for healthcare professionals

MHLW (Japan) approves Lyfnua (gefapixant) to treat refractory or unexplained cough.

Read time: 1 mins
Published:25th Jan 2022
The Japan Ministry of Health, Labor and Welfare (MHLW) has approved Lyfnua (gefapixant) Tablets 45 mg for adults with refractory or unexplained chronic cough.

In Japan, Lyfnua is the planned trademark for gefapixant; the trademark for gefapixant in other countries has not been approved.

Outside of Japan, gefapixant is an investigational treatment and is still under review by other regulatory bodies.

Condition: Chronic Cough
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.